Sat.Mar 18, 2023

article thumbnail

Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data

Bio Pharma Dive

The eagerly anticipated results from a Phase 2 study in psoriasis show why the pharma paid $4 billion to buy the drug from startup Nimbus Therapeutics last year

Drugs 246
article thumbnail

New patent expiration for Acorda drug INBRIJA

Drug Patent Watch

Annual Drug Patent Expirations for INBRIJA Inbrija is a drug marketed by Acorda and is included in one NDA. It is available from one supplier. There are ten patents protecting… The post New patent expiration for Acorda drug INBRIJA appeared first on DrugPatentWatch - Make Better Decisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How CROs can improve their operations to better serve biotech companies

Cloudbyz

Contract Research Organizations (CROs) play a crucial role in helping biotech companies conduct clinical trials and bring drugs to market.

article thumbnail

New patent expiration for Amgen Inc drug OTEZLA

Drug Patent Watch

Annual Drug Patent Expirations for OTEZLA Otezla is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. There are eleven patents… The post New patent expiration for Amgen Inc drug OTEZLA appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

article thumbnail

Pharmaceutical companies with the most ‘New Chemical Entity’ drugs

Drug Patent Watch

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by… The post Pharmaceutical companies with the most ‘New Chemical Entity’ drugs appeared first on DrugPatentWatch - Make Better Decisions. Infographic